Search the Newsreel

CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise

CRISPR Therapeutics (CRSP) stock has seen a significant decline over the past five years but now appears to be fairly valued. Despite promising allogeneic CAR-T programs, its Price-to-Book ratio is in line with the biotech industry average, suggesting investors acknowledge its potential without pricing …

Acrivon Therapeutics Q2 Results: EPS beats estimate, losses narrow 22% YoY

Acrivon Therapeutics reported a Q2 2026 net loss of $18.0 million, which translates to $(0.43) per share, significantly beating analyst estimates by 14% and narrowing losses by 21.82% year-over-year. The improved financial performance was attributed to reduced R&D and G&A expenses. The company holds …

Acrivon Therapeutics (NASDAQ:ACRV) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Acrivon Therapeutics (NASDAQ:ACRV) reported its quarterly earnings, posting a loss of $0.43 per share, which beat analyst expectations by $0.06. Despite this, shares declined by 0.6% to $1.72 during midday trading. The company maintains a "Moderate Buy" consensus rating from analysts, with an average …

Acrivon Therapeutics GAAP EPS of -$0.43 beats by $0.07

* Acrivon Therapeutics press release [https://seekingalpha.com/pr/20617353-acrivon-reports-second-quarter-2026-financial-results-and-highlights-upcoming-2026-clinical] (ACRV [https://seekingalpha.com/symbol/ACRV]): Q2 GAAP EPS of -$0.43 beats by $0.07. * As of June 30, 2026, the company had cash, cash equivalents and investments of $90.0 million, which is expected to fund operating expenses and capital expenditure requirements …

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet …

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …

Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics announced its second-quarter 2026 financial results, reporting a net loss of $18.0 million and $90.0 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q4 2027. The company highlighted upcoming clinical data catalysts for ACR-368, including a Phase …

Carter's (CRI) Is Up 3.60% in One Week: What You Should Know

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …

Stronger Revenue and Narrower Loss Might Change The Case For Investing In CRISPR Therapeutics (CRSP)

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

Noble Financial Predicts Reduced Earnings for E.W. Scripps

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Australian Strategic Materials (ASX:ASM) Takeover Vote Puts Critical Minerals Stock in Focus

Tivan (ASX:TVN) Critical Minerals Strategy Gains Attention Ahead of Speewah Study

Scribe Therapeutics (SCTX): Avoro group reports 16.37% ownership after IPO

Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh have reported a collective beneficial ownership of 16.37% in Scribe Therapeutics, Inc. (SCTX) common stock following the company's IPO. This stake, totaling 3,088,888 shares, arose from the conversion of Series B preferred stock, purchases …

Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Acrivon Therapeutics Inc (ACRV), including analyst ratings, price targets, and expected EPS and revenue figures. Based on ratings from 8 analysts, the stock has a "Buy" trend with a target price of USD 11.50, representing a potential …

Critical Minerals Group Secures Shareholder Backing for Capital and Incentive Resolutions

Critical Metals (CRML) Short Interest & Short Float | Updated Aug 2026

Critical Metals (CRML) reported a significant increase in short interest, with 21.22 million shares sold short as of July 31, 2026, representing 42.12% of the public float and a 24.06% increase from the prior report. The short interest ratio stands at 3.5 days to …

South32 (ASX:S32) Reshapes Portfolio Around Copper and Critical Metals

Critical Minerals Group Details Vanadium Electrolyte Supply Chain Strategy

Cricut, Inc. Earnings Call Balances Growth and Strain

CRISPR Therapeutics (CRSP) CFO Prasad Raju makes bona fide gift of 750 shares

CRISPR Therapeutics AG's Chief Financial Officer, Prasad Raju, reported a bona fide gift of 750 Common Shares on August 7, 2026. This transaction is classified as a disposition, and following the gift, Raju directly holds 14,815 Common Shares. The Form 4 filing indicates the …

Carter's Inc Officer Allison Peterson Withholds 4,426 Shares for Tax on Restricted Stock Vesting

Allison Peterson, Chief Retail & Digital Officer at Carter's Inc (NYSE:CRI), withheld 4,426 common shares on August 9, 2026, to cover tax obligations from a restricted stock vesting event. The shares were valued at $39.96 each. Following this transaction, Peterson beneficially owns 63,297 common …

Carters Inc (CRI) CMO has 2,842 shares withheld to cover tax on vesting

Carters Inc.'s Chief Marketing Officer, Sarah Crockett, reported a Form 4 indicating a tax-related share disposition. On August 8, 2026, 2,842 shares of common stock were withheld at $39.96 per share to cover tax obligations from restricted stock vesting. Following this transaction, Crockett directly …

CARTERS INC (CRI) officer Emily Scanlon has shares withheld for tax on vesting

Emily Scanlon, Chief Strategy Officer at CARTERS INC (CRI), reported a Form 4 transaction indicating that 8,743 shares of common stock were withheld to cover tax obligations stemming from the vesting of restricted stock. The shares were withheld at a price of $39.96 per …

Critical Metals cut at Freedom on Tanbreez feasibility delay, execution risk (CRML:NASDAQ)

Critical Metals (CRML) stock was downgraded by Freedom Broker to Hold from Buy, with the price target cut to $8 from $17. The downgrade is attributed to delays in the Tanbreez rare earth project's feasibility study and execution risks. Critical Metals' stock fell 2.4% …

Scribe Therapeutics (SCTX) CEO receives time- and performance-based option grants

Scribe Therapeutics CEO Benjamin L. Oakes received three option awards for the company's common stock. These include a fully vested grant of 12,969 options on March 13, 2026, and two grants on July 23, 2026: a time-based option for 264,784 shares vesting monthly over …

Scribe Therapeutics (SCTX) CFO gets major option grants and family share buys

Scribe Therapeutics CFO David Parrot received significant equity awards, including time-vested and performance-based stock options totaling over 200,000 shares, both priced at $15.00. He also reported indirect open-market purchases of 2,666 common shares for family members at the same price. These transactions follow a …

Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD

Crinetics Pharmaceuticals (CRNX) stock reached an all-time high of $84.35, reflecting a 196.14% increase over the past year and a current market capitalization of approximately $8.94 billion. Despite its strong performance, InvestingPro data suggests the stock might be overbought and overvalued. The company recently …

Freedom Broker cuts Critical Metals stock rating on project delays

Freedom Broker downgraded Critical Metals (NASDAQ:CRML) from Buy to Hold and lowered its price target due to delays at the Tanbreez project, which increase execution risk and uncertainty. The stock is currently trading below the revised target and has seen a significant decline over …

Immersion Investment Views Strata Critical Medical (SRTA) as a “Babushka Doll”

Immersion Investment Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Immersion Investment Partners returned 39.1% in the second quarter, surpassing the Russell 2000 Index's 21.5% gain. The market started valuing their non-AI …

Genscript Highlights Legend Biotech’s Q2 Results and Cautions Investors

Critical Mineral Resources: Building a copper mining business in Morocco

Critical Mineral Resources PLC (LSE:CMRS, FRA:98J) CEO Charlie Long explains why Morocco is central to the company's strategy, discussing its geological potential, the importance of local partnerships, the balance between exploration and near-term production, and how the long-term copper market supports the company's investment …